145 related articles for article (PubMed ID: 9618864)
21. Immunophenotypic and ultrastructural evidence of the langerhans cell origin of the canine cutaneous histiocytoma.
Marchal T; Dezutter-Dambuyant C; Fournel C; Magnol JP; Schmitt D
Acta Anat (Basel); 1995; 153(3):189-202. PubMed ID: 8984828
[TBL] [Abstract][Full Text] [Related]
22. P-selectin expression in canine cutaneous inflammatory diseases and mast cell tumors.
Chénier S; Doré M
Vet Pathol; 1998 Mar; 35(2):85-93. PubMed ID: 9539361
[TBL] [Abstract][Full Text] [Related]
23. Major histocompatibility class II expression in the normal canine cornea and in canine chronic superficial keratitis.
Williams DL
Vet Ophthalmol; 2005; 8(6):395-400. PubMed ID: 16359362
[TBL] [Abstract][Full Text] [Related]
24. Multiple, resolving, cutaneous histiocytoma in a dog.
Bender WM; Muller GH
J Am Vet Med Assoc; 1989 Feb; 194(4):535-7. PubMed ID: 2537810
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical characterization of the lesions of feline progressive lymphocytic cholangitis/cholangiohepatitis.
Day MJ
J Comp Pathol; 1998 Aug; 119(2):135-47. PubMed ID: 9749358
[TBL] [Abstract][Full Text] [Related]
26. Expression of major histocompatibility complex class II molecules by dermal inflammatory cells, epidermal Langerhans cells and keratinocytes in canine dermatological disease.
Day MJ
J Comp Pathol; 1996 Nov; 115(4):317-26. PubMed ID: 9004075
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical characterization of inflammatory cell populations and adhesion molecule expression in synovial membranes from dogs with spontaneous cranial cruciate ligament rupture.
Lemburg AK; Meyer-Lindenberg A; Hewicker-Trautwein M
Vet Immunol Immunopathol; 2004 Feb; 97(3-4):231-40. PubMed ID: 14741141
[TBL] [Abstract][Full Text] [Related]
28. Patterns of lymphoid infiltrate in the canine cutaneous histiocytoma.
Cockerell GL; Slauson DO
J Comp Pathol; 1979 Apr; 89(2):193-203. PubMed ID: 222817
[No Abstract] [Full Text] [Related]
29. Immunohistochemical and histopathologic features of 14 malignant fibrous histiocytomas from Flat-Coated Retrievers.
Morris JS; McInnes EF; Bostock DE; Hoather TM; Dobson JM
Vet Pathol; 2002 Jul; 39(4):473-9. PubMed ID: 12126150
[TBL] [Abstract][Full Text] [Related]
30. Transport of peptide-MHC class II complexes in developing dendritic cells.
Turley SJ; Inaba K; Garrett WS; Ebersold M; Unternaehrer J; Steinman RM; Mellman I
Science; 2000 Apr; 288(5465):522-7. PubMed ID: 10775112
[TBL] [Abstract][Full Text] [Related]
31. Lineage differentiation of canine lymphoma/leukemias and aberrant expression of CD molecules.
Wilkerson MJ; Dolce K; Koopman T; Shuman W; Chun R; Garrett L; Barber L; Avery A
Vet Immunol Immunopathol; 2005 Jul; 106(3-4):179-96. PubMed ID: 15963817
[TBL] [Abstract][Full Text] [Related]
32. Ovine cutaneous squamous cell carcinoma: immunohistochemical expression of CD3, CD4, CD8 and MHC class II antigens in the associated inflammatory infiltrate.
Mozos E; Méndez A; Martín MP; Herráez P; Pérez J
Vet Immunol Immunopathol; 1998 Feb; 61(2-4):221-8. PubMed ID: 9613436
[TBL] [Abstract][Full Text] [Related]
33. Variation in expression of MHC class II antigens on horse lymphocytes determined by MHC haplotype.
Barbis DP; Bainbridge D; Crump AL; Zhang CH; Antczak DF
Vet Immunol Immunopathol; 1994 Jul; 42(1):103-14. PubMed ID: 7975179
[TBL] [Abstract][Full Text] [Related]
34. Selective immunosuppression by administration of major histocompatibility complex (MHC) class II-binding peptides. I. Evidence for in vivo MHC blockade preventing T cell activation.
Guéry JC; Sette A; Leighton J; Dragomir A; Adorini L
J Exp Med; 1992 May; 175(5):1345-52. PubMed ID: 1569402
[TBL] [Abstract][Full Text] [Related]
35. Effect of tumor infiltrating lymphocytes on the expression of MHC molecules in canine transmissible venereal tumor cells.
Hsiao YW; Liao KW; Hung SW; Chu RM
Vet Immunol Immunopathol; 2002 Aug; 87(1-2):19-27. PubMed ID: 12052339
[TBL] [Abstract][Full Text] [Related]
36. Immunophenotypic characterization of cutaneous lymphoid neoplasia in the dog and cat.
Day MJ
J Comp Pathol; 1995 Jan; 112(1):79-96. PubMed ID: 7722010
[TBL] [Abstract][Full Text] [Related]
37. Selective immunosuppression by administration of major histocompatibility complex class II-binding peptides. II. Preventive inhibition of primary and secondary in vivo antibody responses.
Guéry JC; Neagu M; Rodriguez-Tarduchy G; Adorini L
J Exp Med; 1993 May; 177(5):1461-8. PubMed ID: 8478615
[TBL] [Abstract][Full Text] [Related]
38. An immunohistochemical study of the inflammatory infiltrate associated with nasal carcinoma in dogs and cats.
Vanherberghen M; Day MJ; Delvaux F; Gabriel A; Clercx C; Peeters D
J Comp Pathol; 2009 Jul; 141(1):17-26. PubMed ID: 19362315
[TBL] [Abstract][Full Text] [Related]
39. Upregulation of major histocompatibility complex class II antigens in hepatocytes in Doberman hepatitis.
Speeti M; Ståhls A; Meri S; Westermarck E
Vet Immunol Immunopathol; 2003 Nov; 96(1-2):1-12. PubMed ID: 14522129
[TBL] [Abstract][Full Text] [Related]
40. Dynamics of major histocompatibility complex class II compartments during B cell receptor-mediated cell activation.
Lankar D; Vincent-Schneider H; Briken V; Yokozeki T; Raposo G; Bonnerot C
J Exp Med; 2002 Feb; 195(4):461-72. PubMed ID: 11854359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
